{"task_id": "201abcb5d7202456", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 295/905)", "text": "uting beads; it causes fever and abdo pain in 50%.\n\n--- Page 301 ---\n287\nGastroenterology\nUse hepatitis B vaccine 1mL into deltoid; repeat at 1 & 6 mon ths (child: 0.5mL \u2248 3 \ninto the anterolateral thigh). Indications: Everyone (WHO advice, even in areas \nof \u2018low\u2019 endemicity\u2014in 2014 this meant that 82% of the world\u2019s children received \nprotection against HBV). This contrasts with the approach in eg the UK and USA of \ntargeting at-risk groups (p278). The immunocompromised and others may need \nfurther doses. Serology helps time boosters and \ufb01 nds non-responders (correlates \nwith older age, smoking, and \ue032 sex). \ue007Know your own antibody level!\nTable 6.15 Post-immunization anti-HBs titres and actions\nAnti-HBs (IU/L)\nActions and comments (advice diff ers in some areas)\n>1000\nGood level of immunity; retest in ~4yrs.\n100\u20131000\nGood level of immunity; if level approaches 100, retest in 1yr.\n<100\nInadequate; give booster and retest.\n<10\nNon-responder; give another set of 3 vaccinations. Retest; if <10 get \nconsent to check hepatitis B status: HBSAg +ve means chronic infection; \nanti-HB core +ve represents past infection and immunity. If a non-re-\nsponder is deemed susceptible to HBV, and has recently come in contact \nwith risky bodily \ufb02 uids, off er 2 doses of anti-hep B immunoglobulin.\nNB: protection begins some weeks after dose 1, so it won\u2019t work if exposure is rec-\nent; here, speci\ufb01 c antihepatitis B immunoglobulin is best if not already immunized.\nVaccinating to prevent hepatitis B (and associated complications)\nFig 6.32 Axial CT of the liver \nafter IV contrast showing multiple \nround lesions of varying size, highly \nsuggestive of hepatic metastases.\nCourtesy of Norwich Radiology Dept.\nTable 6.13 Primary liver tumours\nMalignant (prognosis\u2014regardless of \ntype\u2014is poor)\nBenign\nHCC\nCholangiocarcinoma\nAngiosarcoma\nHepatoblastoma\nFibrosarcoma & hepatic gastrointestinal stro-\nmal tumour (GIST\u2020, formerly leiomyosarcoma)\nCysts\nHaemangioma;* common, \ue033:\ue032\u22485:1\nAdenoma\nFocal nodular hyperplasia\nFibroma\nBenign GIST (=leiomyoma)\n* Haemangiomas are hyperechoic on ultrasound; may be part of von Hippel\u2013Lindau syndrome; may need \nsurgery if diagnosis is uncertain (may be confused with HCC) or they are enlarging on 6-monthly US.\n\u2020 GISTs are mesenchymal tumours that are more likely to be found in the gut as a \nspherical mass arising from the muscularis propria, eg with GI bleeding. If unresectable, \nimatinib \ue000 2yr survival from 26% to 76%.\nTable 6.14 Origins of secondary liver tumours\nCommon in men\nCommon in women\nLess common (either sex)\nStomach\nLung\nColon\nBreast\nColon\nStomach\nUterus\nPancreas\nLeukaemia\nLymphoma\nCarcinoid tumours", "text_length": 2648, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 295/905)", "type": "chunk", "chunk_index": 294, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:52.679977", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:52.680849", "status": "complete", "chunks_added": 2}